Huisheng Biotech (300871.SZ) Issues Profit Forecast, Expects 2025 Net Profit Attributable to Shareholders of 235 Million to 271 Million Yuan

Stock News01-09

Wuhan Hvsen Biotechnology Co.,Ltd. (300871.SZ) has disclosed its performance forecast for the 2025 fiscal year. The company anticipates achieving a net profit attributable to shareholders of the listed company in the range of 235 million yuan to 271 million yuan, marking a significant turnaround from a loss to a profit. After deducting non-recurring gains and losses, the net profit is projected to be between 213 million yuan and 249 million yuan.

During the reporting period, the company proactively expanded its market presence both domestically and internationally, resulting in revenue growth in both its domestic and overseas operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170814816?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170814816","market":"sg","top_or_hot":-1,"title":"Huisheng Biotech (300871.SZ) Issues Profit Forecast, Expects 2025 Net Profit Attributable to Shareholders of 235 Million to 271 Million Yuan","media":"Stock News","content":"<p>Wuhan Hvsen Biotechnology Co.,Ltd. (300871.SZ) has disclosed its performance forecast for the 2025 fiscal year. The company anticipates achieving a net profit attributable to shareholders of the listed company in the range of 235 million yuan to 271 million yuan, marking a significant turnaround from a loss to a profit. After deducting non-recurring gains and losses, the net profit is projected to be between 213 million yuan and 249 million yuan.</p>\n<p>During the reporting period, the company proactively expanded its market presence both domestically and internationally, resulting in revenue growth in both its domestic and overseas operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huisheng Biotech (300871.SZ) Issues Profit Forecast, Expects 2025 Net Profit Attributable to Shareholders of 235 Million to 271 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuisheng Biotech (300871.SZ) Issues Profit Forecast, Expects 2025 Net Profit Attributable to Shareholders of 235 Million to 271 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-09 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wuhan Hvsen Biotechnology Co.,Ltd. (300871.SZ) has disclosed its performance forecast for the 2025 fiscal year. The company anticipates achieving a net profit attributable to shareholders of the listed company in the range of 235 million yuan to 271 million yuan, marking a significant turnaround from a loss to a profit. After deducting non-recurring gains and losses, the net profit is projected to be between 213 million yuan and 249 million yuan.</p>\n<p>During the reporting period, the company proactively expanded its market presence both domestically and internationally, resulting in revenue growth in both its domestic and overseas operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300871","symbol_name":"回盛生物","start_time":0,"source_url":"","article_id":"1170814816","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170814816","pubTimestamp":1767946938,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Wuhan Hvsen Biotechnology Co.,Ltd. (300871.SZ) has disclosed its performance forecast for the 2025 fiscal year. The company anticipates achieving a net profit attributable to shareholders of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300871":"回盛生物","BK0239":"医药制造"},"translate_title":"惠生生物（300871.SZ）发布盈利预告，预计2025年归属股东净利润2.35亿元-2.71亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300871":1},"content_text":"Wuhan Hvsen Biotechnology Co.,Ltd. (300871.SZ) has disclosed its performance forecast for the 2025 fiscal year. The company anticipates achieving a net profit attributable to shareholders of the listed company in the range of 235 million yuan to 271 million yuan, marking a significant turnaround from a loss to a profit. After deducting non-recurring gains and losses, the net profit is projected to be between 213 million yuan and 249 million yuan.\nDuring the reporting period, the company proactively expanded its market presence both domestically and internationally, resulting in revenue growth in both its domestic and overseas operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170814816","isCrawlerRequest":true}